H.C. Wainwright BioConnect Conference
For Fiscal Year Ending Dec 31, 2019
Receive updates straight into your inbox
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.
955 Chesterbrook Blvd Suite 110 Chesterbrook, PA 19087
T: (610) 354-8840
LifeSci Advisors, LLC Dan Ferry Managing Director T: 617-430-7576 email@example.com